Published on by Top Pharmaceutical

Yongxiang Zhao | Gene Therapy | Best Researcher Award

Prof. Dr Yongxiang Zhao,Guangxi Medical University,China

Prof. Dr. Yongxiang Zhao, Director of the State Key Laboratory of Targeted Oncology, is a renowned expert in tumor diagnosis and treatment. A recipient of the Ho Leung Ho Lee Award 🏆 and a leader in the Yangtze River Scholars Award Program, he pioneered the world’s first gene-edited liver cancer monkey model 🧬 and developed the first intravenous recombinant NDV oncolytic virus 🦠, showing a 90% disease control rate in Phase III trials. With over 160 SCI papers 📄 and 46 invention patents, he has led 30+ major drug development projects, shaping the future of cancer therapy. 🚀

Publication Profile

Scopus

Outstanding Leadership and Recognition

Prof. Dr. Yongxiang Zhao 🎓 is a globally renowned researcher and a visionary leader in the scientific community. As the Director of the State Key Laboratory of Targeted Oncology 🏥, he has spearheaded groundbreaking advancements in cancer research. His outstanding achievements have earned him prestigious honors, including the Ho Leung Ho Lee Award 🏆. Additionally, he leads national innovation programs such as the Yangtze River Scholars Award Program Innovation Team 🌊 and the Ten Thousand Talents Program 🌟. These recognitions underscore his influential role in shaping the future of scientific discovery and fostering innovation on a national and international scale.

Contributions to Oncology

Prof. Dr. Yongxiang Zhao 🎓 has made groundbreaking contributions to oncology, particularly in targeted tumor diagnosis and treatment. He pioneered the development of the world’s first gene-edited liver cancer monkey model 🧬🐒, a revolutionary advancement that has transformed cancer research. This innovative model provides an exceptionally accurate system for studying liver cancer, paving the way for more effective treatment strategies 💊. His work has significantly enhanced our understanding of tumor progression and therapeutic interventions, solidifying his reputation as a leader in oncology 🔬. Through his pioneering research, Dr. Zhao continues to drive innovation and shape the future of cancer treatment.

Breakthrough Innovations in Cancer Treatment

Prof. Dr. Yongxiang Zhao 🎓 has achieved a groundbreaking milestone in cancer treatment with the development of the world’s first intravenous recombinant Newcastle Disease Virus (NDV) oncolytic virus 🦠💉. This revolutionary therapy targets 13 advanced cancers, including liver cancer, offering a promising new approach to oncology. Multi-center clinical trials demonstrated an impressive Disease Control Rate (DCR) of 90% 📊, leading to Phase III clinical trials. This breakthrough has the potential to transform cancer therapy, providing new hope to patients worldwide 🌍. Dr. Zhao’s innovative work continues to push the boundaries of medical science, redefining the future of cancer treatment.

Extensive Research and Intellectual Property

Prof. Dr. Yongxiang Zhao 🎓 is a prolific researcher whose contributions have profoundly impacted oncology and drug development. With over 160 SCI publications 📄, including influential papers in top-tier journals like Cell 🧬, his work has advanced scientific understanding in the field. His innovative mindset is reflected in 46 invention patents 🏅, highlighting his role as a pioneer in medical research. Leading over 30 major national drug development projects 💊, Dr. Zhao has played a crucial role in translating groundbreaking discoveries into real-world medical applications, shaping the future of cancer treatment and improving patient outcomes globally 🌍.

Research Focus

Dr. Yongxiang Zhao’s research primarily focuses on nanomedicine, drug delivery systems, and cancer therapeutics. His work spans polymeric nanoparticles 🧪, exosomal RNA therapies 🧬, and aptamer-based antiviral strategies 🦠, particularly targeting multidrug-resistant bacterial infections and cancer treatment 🎗️. He also explores biocompatible microspheres for tissue repair 🏥 and oncology-focused biomaterials. His research integrates biomedical engineering 🏗️, molecular biology 🧫, and clinical applications. Dr. Zhao’s contributions extend to tumor microenvironment studies, cancer-associated fibroblasts 💊, and immunotherapeutic bacteria 🦠 for precision medicine, making significant strides in advanced therapeutics and biomaterials development.

Publication Top Notes

Moxifloxacin-Loaded Polymeric Nanoparticles for Overcoming Multidrug Resistance in Chronic Pulmonary Infections Caused by Pseudomonas aeruginosa

The function of albumin and its application in tumor therapy

Aptamers targeting SARS-CoV-2 nucleocapsid protein exhibit potential anti pan-coronavirus activity

Heterogeneity and interplay: the multifaceted role of cancer-associated fibroblasts in the tumor and therapeutic strategies

Exosomal lncRNA ROR1-AS1 from cancer-associated fibroblasts inhibits ferroptosis of lung cancer cells through the IGF2BP1/SLC7A11 signal axis

Correction to: Engineering a precise adenine base editor with minimal bystander editing (Nature Chemical Biology, (2023), 19, 1, (101-110), 10.1038/s41589-022-01163-8)

Polymer Microspheres and Their Application in Cancer Diagnosis and Treatment

Microalgae-loaded biocompatible alginate microspheres for tissue repair

Landscape of global urban environmental resistome and its association with local socioeconomic and medical status

Oncolytic mineralized bacteria as potent locally administered immunotherapeutics

Yongxiang Zhao | Gene Therapy | Best Researcher Award

You May Also Like